Company Overview
Snapshot
Founded in July 2019 by Boaz Shenhav, Bio Refine operates with 1–10 employees. The company has raised $900,000 across two funding rounds from one investor. In October 2025, Bio Refine secured follow-on funding from Peregrine Ventures.
Business overview
Bio Refine is a Health Tech & Life Sciences company focused on developing an endovascular annuloplasty remodeling system for the repair of mitral and tricuspid heart valves. This technology offers an implantless solution designed to treat patients who are currently at high risk for open surgery. The system utilizes a standard endovascular approach, aiming for a safe, repeatable procedure that does not preclude ancillary interventions. Bio Refine operates in the Medical Devices and Medical Treatment & Therapeutics sectors, serving healthcare providers.
Log in to access full profile ›Company Intelligence Q&A
- What is Bio Refine's core technology?
- Bio Refine has developed an endovascular annuloplasty remodeling system designed for the repair of mitral and tricuspid heart valves without the need for an implant. This technology aims to provide a treatment option for patients who cannot undergo traditional open surgery due to high risks.
- When was Bio Refine founded and by whom?
- Bio Refine was founded in July 2019 by Boaz Shenhav, who serves as Co-Founder & CEO.
- What was Bio Refine's last funding event?
- In October 2025, Bio Refine received follow-on funding from Peregrine Ventures.
- What was Bio Refine's initial funding round?
- In February 2023, Bio Refine secured $900,000 in Pre-Seed funding from Peregrine Ventures.
- What are the key advantages of Bio Refine's solution?
- Bio Refine's implantless solution offers several advantages, including easier regulatory processes, the use of a standard endovascular approach, and a procedure that is safe, repeatable, and does not prevent ancillary procedures.